Last reviewed · How we verify

NCT06623123

Oto Smartphone App in Treating Tinnitus Amongst Adult Patients Compared with Standard Talking Therapies

Recruiting now Phase 3 Last updated 2 October 2024
What this trial tests

Phase 3 trial testing Oto Smartphone Application (Oto Health Ltd) in Tinnitus in 160 participants. Currently enrolling.

Timeline
20 June 2024
Primary endpoint
20 June 2025
20 June 2025

Quick facts

Lead sponsorEast and North Hertfordshire NHS Trust
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment160
Start date20 June 2024
Primary completion20 June 2025
Estimated completion20 June 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

East and North Hertfordshire NHS Trust

Who can join

18 and older, any sex, with Tinnitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study that looks at treating tinnitus and its associated burden, insomnia and quality of life effects with a smartphone app when compared with the talking therapies already offered on the national health service. Three separate questionnaires will be used to collect this data from patients at regular time intervals.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Multimodality Smartphone App Delivered Therapy for Tinnitus – A Protocol for a Randomised Controlled Trial
    Habeeb A, Vijendren A. · · 2026 · DOI 10.21203/rs.3.rs-7908701/v1

Verify or expand the search:

Other recruiting trials for Tinnitus

Currently open trials in the same condition.

Other East and North Hertfordshire NHS Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06623123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing